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Abstract
Background: Thymic carcinoma (TC) is a rare type of malignant neoplasm that develops in the anterior
mediastinum and associated with poor prognosis. Type B3 thymoma (B3) occasionally demonstrates malignant
tumor characteristics, especially in the advanced stage. We investigated the expressions of tumor-related genes in
resected TC and B3 specimens.
Methods: TC and B3 specimens resected from 1999 through 2012 were investigated. Tumor segments were
collected from the specimens by micro-dissection to extract mRNA, then RT-PCR was performed according to
Dannenberg’s tumor profile method for semi-quantitation of tumor-related gene mRNA. To compare with other
types of cancer, data from lung cancer (LC) cases in our database were also examined.
Results: The gene expression levels of thymidylate synthase were significantly higher in TC and B3 as compared to
LC specimens (p < 0.02), while no difference were observed between TC and B3 tumors. The ratio of
folypolyglutamyl synthase (FPGS) to gamma-glutamyl hydrolase (GGH) mRNA was significantly lower in TC than in
B3 (p < 0.05), with lower FPGS/GGH in those tumors related to overall survival. Also, the gene expression of vascular
endothelial growth factor (VEGF) was significantly higher in TC as compared to B3 (p = 0.04), with higher VEGF gene
expression in TC and B3 specimens related to overall survival of affected patients. Epidermal growth factor receptor
(EGFR) expression was significantly higher in B3 as compared to both TC and LC specimens (p < 0.01). However,
there were no EGFR gene mutations detected in any of the specimens.
Conclusions: These results indicate that elevated expressions of the tumor-related genes FPGS/GGH and VEGF are
correlated with malignancy of TC and B3 tumors. Additional examinations will be necessary to investigate their
chemosensitivity.
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Background
A thymic carcinoma (TC) is a rare type of malignant
neoplasm that develops in the anterior mediastinum and
associated with poor prognosis [1]. Although all types of
thymoma have a malignant potential, type B3 (B3), espe-
cially in an advanced stage, shows a poor prognosis, the
same as TC [1, 2]. Complete surgical resection is the
preferred treatment to achieve a cure in B3 cases,
while patients with metastatic or recurrent tumors are
candidates for systemic chemotherapy. Platinum-based pro-
tocols are used for first-line chemotherapy to treat these
thymic epithelial tumors, and recently the expressions of
various tumor-related genes have been reported to correlate
with the chemo-sensitivity of several types of cancer and
prognosis of affected patients [3–6]. Furthermore, several
studies have compared gene expression levels in TC and
thymoma cases [7]. In the present study, we investigated
the expressions of tumor-related genes in these rare tumors
to establish an appropriate treatment strategy.
Methods
Specimens resected from consecutive patients with TC
or B3 who underwent surgery from January 1999
through April 2012 at our institutions were investigated.
To compare with lung cancer (LC) tumors, several char-
acteristics of LC cases in our database [8, 9] were also
examined. We found 49 cases of adenocarcinoma (AD)
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and 49 of squamous cell carcinomas (SCC) in the data-
base, and used them for comparisons. Of the ADs, 26, 8,
and 15 were stage I, II, and III, respectively, while those
stages were seen in 32, 7, and 10, respectively, of the
SCC cases. Sixteen patients with AD and 12 with SCC
had a relapse during the observation period. The
Dokkyo Medical University Hospital Ethics Committee
approved this retrospective study (#24036) and waived the
need for patient consent for analysis of the results.
Determination of tumor-related gene expression
Excised specimens were thinly sliced, then tumor seg-
ments were collected by micro-dissection to extract
mRNA. Real time polymerase chain reaction (RT-PCR)
assays were performed according to Danenberg’s tumor
profile (DTP) method [10] for semi-quantitation of
mRNA of tumor-related genes (Response Genetics Inc.,
New York, USA), including thymidylate synthase (TS),
dihydropyrimidine dehydrogenase (DPD), thymidine
phosphorylase (TP), dihydrofolate reductase (DHFR),
gamma-glutamyl hydrolase (GGH), folypolyglutamyl syn-
thase (FPGS), vascular endothelial growth factor (VEGF),
excision repair cross-complementation group 1 (ERCC1),
topoisomerase-1 (TOPO1), and epidermal growth factor
receptor (EGFR). In brief [8, 10], a laser-captured micro-
dissection technique was used with 10-μm sections at a
magnification of 100x to obtain only cancer cells. Next,
1500–2000 round spots 80 μm in diameter were dissected
for each case, from which total RNA was extracted. Real-
time quantitative reverse transcription-PCR assays were
performed with those samples using an ABI 7700 and
TaqMan Probes. The level of ß-actin mRNA was used as a
reference. Relative gene expression values are expressed as
the ratio of PCR products of the gene of interest to that of
ß-actin, the internal reference gene.
EGFR mutation
Tumor tissues were obtained from the patients and
placed as formalin-fixed paraffin-embed samples on slide
glasses. Detection of the EGFR mutation in each speci-
men was performed using a peptide nucleic acid-locked
nucleic acid (PNA-LNA) PCR clamp assay (SRL Inc.,
Tokyo, Japan).
Statistics
Values are shown as the mean ± SD. An unpaired t test
with Welch correction was used for comparing between
2 groups. For non-parametric data, a Mann–Whitney
test was used. Analysis of variance (ANOVA) was uti-
lized for comparing among 3 or more groups, then
Tukey’s post-hoc test was used when significance was
found. Survival rate was calculated by the Kaplan-Meier
method. A log-rank test was used for comparisons
among groups. Receiver operating characteristic (ROC)
curve analysis was done to estimate optimal sensitivity
and specificity for prediction of overall survival according
to different cutoff levels of relative gene expression value.
Statistical calculations were performed using GraphPad
Prism 6 (GraphPad Software Inc., La Jolla, CA. USA).
Differences were considered significant at P < 0.05.
Results
Among 76 patients who underwent surgery for thymic
epithelial tumors at our institution, 14 had TC (18.4 %)
and 8 had B3 (10.5 %). Patient characteristics are shown
in Table 1.
Nucleotide-metabolism-related enzymes
Gene expression levels of TS, DPD, and TP in the TC
specimens were compared to those in the B3 specimens,
and also compared to those in lung ADs and SCCs. The
relative gene expression value of TS was 7.93 ± 7.82 in TC,
10.87 ± 9.41 in B3, 1.60 ± 0.86 in lung AD, and 4.33 ± 3.35
in lung SCC (Fig. 1a). That value was significantly lower in
lung AD as compared to the others (p < 0.001), and lower
in lung SCC as compared to both TC (p = 0.02) and B3
(p < 0.01). The relative gene expression value of DPD
was 1.14 ± 0.95 in TC, 1.67 ± 1.28 in B3, 2.29 ± 1.22 in
lung AD, and 1.52 ± 1.20 in lung SCC (Fig. 1b). That
value was significantly higher in lung AD as compared
to both lung SCC (p = 0.01) and TC (p < 0.01). The relative
gene expression value of TP was 26.42 ± 34.36 in TC,
14.36 ± 5.18 in B3, 9.52 ± 6.30 in lung AD, and 16.27 ±
11.84 in lung SCC (Fig. 1c). That value was significantly
lower in lung AD as compared to lung SCC (p < 0.01).
Folate-metabolism-related enzymes
Gene expression levels of DHFR, GGH, and FPGS in the
TC specimens were compared to those in the B3 speci-
mens. The relative gene expression value of DHFR was
7.31 ± 5.33 in TC and 5.83 ± 3.90 in B3 (Fig. 2a), which
was not significantly different. The relative gene expres-
sion value of GGH was 2.91 ± 2.71 in TC and 0.93 ± 0.84
in B3 (Fig. 2b), which was significantly higher in the TC
Table 1 Patient characteristics in thymic cancer and B3
thymoma groups
Thymic cancer B3 thymoma
Sex
Male/female 7/7 3/5
Age in years (range) 61.5 (36–82) 51.5 (36–78)
Induction therapy 0/14 0/8
Status at time of study
Alive 2 6
Alive with relapse 2 1
Dead 10 1
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specimens (p = 0.02). The relative gene expression value
for FPGS was 0.45 ± 0.20 in TC and 0.63 ± 0.17 in B3
(Fig. 2c), which was significantly different (p < 0.05). The
ratio of FPGS and GGH (FPGS/GGH) was 0.72 ± 1.36 in
TC and 1.48 ± 1.39 in B3 (Fig. 2d), significantly lower in
the TC specimens (p < 0.05).
Other tumor-related gene expressions
The relative gene expression values for VEGF, ERCC1,
TOPO1, and EGFR in the TC and B3 specimens were
compared to those in LC specimens. The relative gene
expression value for VEGF was 10.1 ± 10.1 in TC, 1.42 ±
0.46 in B3, and 7.72 ± 6.26 in LC (Fig. 3a), which was
Fig. 1 Comparison of relative gene expression of nucleotide-metabolism-related enzymes. a thymidylate synthase, b dihydropyrimidine dehydrogenase,
c thymidine phosphorylase. AD, lung adenocarcinoma (n = 49); SCC, lung squamous cell carcinoma (n = 49); TC, thymic cancer (n = 14); B3,
B3 thymoma (n = 8)
Fig. 2 Comparison of relative gene expression of folate-metabolism-related enzymes. a dihydrofolate reductase (DHFR), b gamma-glutamyl
hydrolase (GGH), c: folypolyglutamyl synthase (FPGS), d FPGS/GGH. TC, thymic cancer (n = 14); B3, B3 thymoma (n = 8 for DHFR, n = 7 for others)
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significantly lower in B3 as compared to TC (p = 0.04).
The relative gene expression value for EGFR was 4.85 ±
3.45 in TC, 13.8 ± 8.3 in B3, and 4.22 ± 4.77 in LC (Fig. 3b),
which was significantly higher in B3 as compared to TC
(p < 0.01) and LC (p < 0.01). On the other hand, there were
no EGFR gene mutations found in the TC and B3 speci-
mens. The relative gene expression value for ERCC1 was
3.62 ± 1.83 in TC, 3.60 ± 1.79 in B3, and 1.80 ± 0.58 in LC
(Fig. 3c), which was significantly higher in TC as com-
pared to LC (p = 0.03). The relative gene expression value
for TOPO1 was 4.02 ± 1.10 in TC, 3.28 ± 1.34 in B3, and
2.63 ± 0.73 in LC (Fig. 3d), which was significantly higher
in TC as compared to LC (p = 0.01).
Analysis of survival in relationship to gene expressions
As described above, the gene expression levels of FPGS,
GGH, VEGF, and EGFR were different between TC and
B3. To determine whether relative gene expression has an
effect on overall survival, the cut-off values for FPGS/
GGH, VEGF, and EGFR were calculated using ROC curve
analysis and shown to be 0.21, 2.19, and 2.52, respectively.
Overall survival curves are presented in Fig. 4. A higher
value for FPGS/GGH was related to significantly superior
survival as compared to a lower value (p = 0.001), while a
lower value for VEGF was related to significantly superior
survival as compared to a higher value (p = 0.0001). There
were no statistically significant differences regarding sur-
vival between higher and lower values of EGFR (p = 0.282).
Discussion
Among thymic epithelial tumors, TC is recognized as a
distinct entity from thymoma [1], while B3 is considered
to be a low-grade malignant tumor, and intermediate be-
tween TC and other types of thymoma [1, 2]. Patients
with metastatic or recurrent TC or B3 tumors are candi-
dates for systemic chemotherapy, and platinum-based
protocols are standard first-line chemotherapy options
for thymic tumors [4, 11]. In the present study, we in-
vestigated tumor-related gene expressions of TC and B3.
As for nucleotide-metabolism-related enzymes, TC and
B3 had a higher gene expression level of TS as compared
to lung AD and SCC. As for folate-metabolism-related
enzymes, the FPGS/GGH ratio was higher in B3 as com-
pared to TC, while VEGF gene expression was much
higher in TC than in B3. Furthermore, a higher value for
FPGS/GGH gene expression and a lower value for VEGF
were associated with superior overall survival. EGFR gene
expression was higher in B3 than in TC, though no EGFR
mutations were found in either the B3 or TC specimens.
Gene expression levels of the nucleotide-metabolism-
related enzymes TS, DPD, and TP in TC and B3 were
compared to those in lung AD and SCC cases listed in
our database. Anti-metabolic drugs, such as pemetrexed,
gemcitabine, and 5-fluorouracil and its derivatives, are
widely used as cancer chemotherapy agents, and their ef-
fects include inhibition of TS, as well as incorporation of
its metabolites into RNA and DNA. TP catalyzes the
synthesis of active metabolites, resulting in disruption of
the activities of TS and DNA, as well as RNA synthesis.
Lower TS activity is thought to be correlated with
greater sensitivity to anti-metabolic drugs [8, 10]. The
present findings showed that gene expression levels of
TS mRNA in TC and B3 were significantly higher than
in lung AD and SCC. Furthermore, the level of DPD
Fig. 3 Expressions of other genes. a vascular endothelial growth factor, b: epidermal growth factor receptor, c excision repair cross-complementation
group 1, d topoisomerase-1. LC, lung cancer (n = 9); TC, thymic cancer (n = 14); B3, B3 thymoma (n = 8)
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mRNA in TC was lower than in lung AD, while it was
similar to that in lung SCC. The gene expression level of
TP mRNA in TC and B3 was not different as compared
to that in LC, whereas that level in lung AD was lower
than in lung SCC. Generally, lung AD is thought to be
more sensitive to anti-metabolic drugs as compared to
lung SCC. Although our results do not directly show the
level of chemosensitivity of these tumors, they indicate
that TC and B3 are likely not as sensitive to anti-
metabolic drugs as lung AD.
We also compared gene expression levels of the folate-
metabolism-related enzymes DHFR, GGH, and FPGS, as
well as the FPGS/GGH ratio between TC and B3. Folate
deficiency increases the risk of cancer development by
induction of an imbalance in DNA precursors and alter-
ing DNA methylation [12]. DHFR is a target enzyme of
methotrexate (MTX), an inhibitor of folate metabolism.
Kawakami et al. reported that the mRNA level of DHFR
in a tumor was correlated with chemo-sensitivity for
MTX [13]. FPGS converts reduced-folate monogluta-
mate to polyglutamate in an intracellular manner, which
results in retention of MTX-polyglutamate inside the
cells. On the other hand, GGH catalyzes the degradation
of inter- and intracellular polyglutamate [14]. Folate
polyglutamate regulates the reaction rate of the key en-
zyme for metabolism, thus FPGS/GGH ratio is import-
ant for folate metabolism, with a higher ratio thought to
be correlated with greater sensitivity to anti-metabolic
drugs including anti-folate agents [14]. We found that a
higher FPGS/GGH gene expression ratio value was asso-
ciated with significantly superior survival as compared
to a lower value, with a cutoff value of 0.21. Therefore,
it is likely that FPGS/GGH ratio plays an important role
in survival of patients with TC and B3, and that B3 is
more sensitive to anti-folate drugs as compared to TC.
VEGF is a signal protein that stimulates angiogenesis
and anti-VEGF therapies are important for treatment of
certain cancers, because solid tumors do not grow be-
yond a limited size without an adequate blood supply
provided by angiogenesis using VEGF signals. VEGF
gene expression in TC was higher than that in B3, while
higher VEGF gene expression in TC and B3 was related
to worse overall survival. These results indicate that
VEGF mRNA expression is correlated with malignancy,
thus anti-VEGF therapy may be a potential candidate for
patients with higher levels of VEGF gene expression.
Several studies have reported that EGFR is overex-
pressed in thymomas and TCs, with higher EGFR staining
significantly associated with stage III-IV cases [3, 15]. The
level of EGFR mRNA was higher in B3 than in both TC
and LC in the present study. However, no EGFR muta-
tions were detected in the B3 and TC specimens. Several
previous reports have also noted that EGFR mutations are
rare in thymic malignancies [3, 16]. Furthermore, Nakagiri
et al. reported a case in which gefitinib therapy failed to
reduce tumor size and also noted an EGFR mutation
caused by exon 19 deletion [17]. Thus, an EGFR-tyrosine
kinase inhibitor is an unlikely candidate for treatment of
TC and B3 patients.
ERCC1 protein is involved in nucleotide excision re-
pair of damaged DNA and determination of ERCC1
mRNA expression may be clinically useful for cancer
treatment, as one of the mechanisms of resistance to
platinum chemotherapy drugs has been shown to be
Fig. 4 Overall survival in relation to gene expression. a ratio of folypolyglutamyl synthase to gamma-glutamyl hydrolase (FPGS/GGH), High, ≥0.21
(n= 14); Low, <0.21 (n= 7), b vascular endothelial growth factor (VEGF), High, >2.19 (n= 12); Low, ≤2.19 (n= 10), c excision repair cross-complementation
group 1 (ERCC1), High, ≥2.52 (n= 15); Low, <2.52 (n= 7)
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correlated with high ERCC1 activity [18, 19]. We found
that the gene expression level of ERCC1 mRNA was
higher in the present TC specimens as compared to LC.
However, our findings are limited and do not fully reveal
the efficacy of platinum-based chemotherapy, though
cisplatin is considered to be a candidate for TC treat-
ment. Furthermore, TOPO-1, which is involved in cell
division, is a target of some anti-cancer drugs, including
irinotecan, topotecan, and camptothecin. Several reports
have shown that higher TOPO-1 protein levels are cor-
related with good clinical outcome [20]. In the present
TC specimens, TOPO-1 gene expression was higher as
compared to the LC specimens.
The present study is limited by its design as an institu-
tional report and the small population, due to rarity of
the disease. Additional studies and case accumulation
are necessary.
Conclusion
Tumor-related gene expressions were analyzed in TC,
B3, and LC specimens. Folate metabolism, as represented
by FPGS/GGH gene expression ratio, was different
between TC and B3, and a higher ratio was associated
with significantly superior survival as compared to a
lower ratio. Furthermore, VEGF gene expression in
TC was higher than that in B3, while higher VEGF
gene expression in TC and B3 was related to worse
overall survival. These results indicate that these gene
expressions are correlated with malignancy in TC and
B3 cases. Additional examinations are necessary to
evaluate the chemosensitivity of these tumors.
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